1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Dr Reddy’s CEO Sees Strength Through Diversity

Erez Israeli Explains The Indian Giant’s ‘Two-Horizon’ Approach To Its Business

 
• By Dave Wallace

With Dr Reddy’s organization now spanning a range of innovative interests and CDMO activities as well as the firm’s traditional small-molecule generics and burgeoning biosimilars businesses, CEO Erez Israeli talked to Generics Bulletin about how these various areas were complementary thanks to the Indian giant’s ‘two-horizon’ approach.

Erez Israeli, Dr Reddy's CEO
Erez Israeli spoke to Generics Bulletin about Dr Reddy’s strategy • Source: Dr Reddy's

Despite having its initial roots in active pharmaceutical ingredients, generics and later biosimilars, Dr Reddy’s is increasingly exploring new ventures in the innovative arena. The firm has more recently branched out into areas including nutraceuticals and immuno-oncology new chemical entities, is placing a greater emphasis on contract development and manufacturing activities, and is exploring new frontiers in digital health and cell and gene therapy.

Speaking to Generics Bulletin in the first part of an exclusive two-part interview, CEO Erez Israeli has set out how the firm’s more innovative interests can not only coexist with its off-patent

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.